Bridge crossed by HeartWare
Tuesday, 23 September, 2008
The US FDA has approved the left ventricular assist system [LVAS] developed by HeartWare [ASX: HTW] for an Investigational Device Exemption (IDE).
The company is now clear to conduct clinical trials of the device, which are to be held at the Washington Hospital Centre, with one patient already enrolled.
The trial is a bridge-to-transplant trial in patients with end-stage heart failure.
HeartWare is in the process of finalising contractual arrangements at a number of additional centres. Seven centres so far have been trained in the use of the product.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
